Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Andernach – page 12

605 clinical trials in Andernach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Andernach at a glance
605
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

605 trials in Andernach

Open in trial search

Study of Elsunersen in Children with SCN2A Developmental and Epileptic Encephalopathy to Reduce Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Elsunersen
  • Sponsor:Praxis Precision Medicines Inc.

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Breast cancer+1

Recruiting

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Institut Für Frauengesundheit GmbH

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Study of empagliflozin compared to placebo in patients with acute decompensated heart failure who are already taking SGLT2 inhibitors

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:AAV-ABCA4-Int-C
  • Sponsor:Splicebio S.L.

Efficacy of 177Lu-DOTATATE as Adjuvant Therapy After Surgery for Stage III Small Intestinal Neuroendocrine Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) oxodotreotide
  • Sponsor:Philipps-Universitaet Marburg

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Andernach

What the registry says about research in the country

01 Analytical, Diagnostic and Therapeutic Techniques and Equipment

Researchers in Andernach are evaluating innovative cell‑based therapies and delivery platforms aimed at repairing knee cartilage damage.

  • Safety profile of UC‑MSC applied on a collagen scaffold
  • Use of Chondro‑Gide® as a supportive matrix
  • Development of minimally invasive implantation methods
  • Implementation of quantitative outcome tools such as KOOS

Both studies are actively recruiting at the sole research site in Andernach, aiming to generate data that could inform future diagnostic and therapeutic standards.

02 Musculoskeletal Diseases

Clinical efforts focus on restoring damaged knee joint cartilage, a prevalent musculoskeletal concern.

  • Evaluation of minced cartilage implantation (AMCI) versus matrix‑associated autologous chondrocyte implantation
  • Management of full‑thickness knee cartilage lesions
  • Assessment of functional recovery through KOOS scores
  • Exploration of long‑term joint health outcomes

The trials seek to improve treatment options for patients with large cartilage injuries and reflect Andernach’s commitment to advancing musculoskeletal research.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.